Supplements Companies Are Cashing In on the Ozempic Wave

  • 📰 WIRED
  • ⏱ Reading Time:
  • 15 sec. here
  • 5 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 51%

Science Nachrichten

Health,Drugs,The Age Of Ozempic

With demand for GLP-1 drugs sky-high, the supplement industry is elbowing into the market. Some products are meant to complement meds like Ozempic. Others are positioned as “natural” alternatives.

Two different types of supplements are glomming onto the popularity of GLP-1 agonist drugs like semaglutide and tirzepatide, which mimic a natural appetite-suppressing, blood-sugar-regulating hormone called glucagon-like peptide-1. First, there’s a rise in efforts to market supplements as complementary to GLP-1 drugs.

Supergut CEO Marc Washington told WIRED that the company’s sales in 2024 were three to four times previous years’ sales as a result of increased interest in non-pharmaceutical ways to increase GLP-1 production. Some health experts question whether these offerings are worthwhile.

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 555. in DE

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Herkunft: ForbesTech - 🏆 318. / 59 Weiterlesen »

Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Herkunft: Forbes - 🏆 394. / 53 Weiterlesen »

For companies in the Ozempic-fueled weight-loss economy, it's survival of the fittestAs powerful anti-obesity drugs become more widely available, companies are repositioning themselves with new products and services.
Herkunft: latimes - 🏆 11. / 82 Weiterlesen »